Photo from Uromigos/X
Oct 12, 2024, 00:33
PD-1 therapy rechallange after adjuvant pembrolizumab in renal cancer – Uromigos
Uromigos shared on X:
” The uromigos Live 2024 meeting asked some questions.
Here is one about PD-1 therapy rechallange after adjuvant pembrolizumab in renal cancer. These 2 polls clearly show the 1 year gap from the time of adjuvant Pembrolizumab changes everything.
This is despite 2 negative randomised rechallange trials in advanced disease. Is there something special about a 1 year interval or the adjuvant setting.
Have the group got this right?”
Source: Uromigos/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 16, 2025, 17:18
Jan 16, 2025, 16:45
Jan 16, 2025, 16:28
Jan 16, 2025, 16:10
Jan 16, 2025, 16:03
Jan 16, 2025, 15:57
Jan 16, 2025, 15:50
Jan 16, 2025, 15:46